Hezkue (Sildenafil)

Hezkue is prescribed for specific medical conditions where increased blood flow can improve symptoms.

• Treatment of erectile dysfunction in adult males.
• Management of pulmonary arterial hypertension to improve exercise capacity.
• Adjunct therapy for certain cases of secondary erectile dysfunction related to diabetes or cardiovascular disease.
• Off‑label use in selected patients with Raynaud’s phenomenon under specialist supervision.
• May be considered in combination with lifestyle modifications for overall vascular health.
• Support for improving endothelial function in patients with chronic heart failure when other therapies are insufficient.
• Potential benefit in reducing symptoms of altitude‑related hypoxia in specialized clinical settings.

• Sildenafil selectively inhibits the enzyme phosphodiesterase type 5 (PDE5) found in smooth muscle cells of the corpus cavernosum and pulmonary vasculature. By blocking PDE5, the drug prevents the breakdown of cyclic guanosine monophosphate (cGMP), allowing cGMP levels to remain elevated. The increased cGMP promotes relaxation of smooth muscle and vasodilation, which enhances blood flow to the targeted tissues. This mechanism underlies its therapeutic effect in both erectile dysfunction and pulmonary arterial hypertension.

Adverse reactions to Hezkue may vary in frequency and severity.

Common

• Headache
• Flushing
• Nasal congestion
• Dyspepsia or indigestion
• Visual disturbances such as blurred vision or a blue tint
• Nausea
• Dizziness
• Back pain
• Dry mouth
• Muscle aches

Serious

• Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy)
• Sudden hearing loss
• Priapism (prolonged erection lasting more than 4 hours)
• Severe hypotension, especially when combined with nitrates
• Cardiovascular events such as myocardial infarction or stroke in high‑risk patients
• Seizures (rare)
• Severe allergic reactions such as rash or angioedema

Before using Hezkue, certain health considerations should be reviewed to minimize risk.

• Patients with known cardiovascular disease should be evaluated by a physician.
• Use is contraindicated in individuals taking nitrates or nitric oxide donors.
• Caution is advised for those with severe renal or hepatic impairment.
• Men with anatomical deformation of the penis (e.g., Peyronie's disease) should discuss risks with a doctor.
• Hezkue should be avoided in patients with a history of non‑arteritic anterior ischemic optic neuropathy.
• Use during pregnancy or breastfeeding is not recommended due to insufficient data.

Hezkue can interact with other medicines, affecting its safety or effectiveness.

Avoid

• Nitrates (e.g., nitroglycerin, isosorbide dinitrate) because of risk of severe hypotension.
• Nitric oxide donors such as riociguat.
• Guanylate cyclase stimulators.
• Certain antifungal agents (e.g., ketoconazole, itraconazole) that markedly increase sildenafil levels.
• Alpha‑blockers in patients with cardiovascular disease (may cause additive blood pressure lowering).

Use with caution

• Antihypertensive drugs (e.g., beta‑blockers, ACE inhibitors) – monitor blood pressure.
• Protease inhibitors (e.g., ritonavir) – may increase sildenafil exposure.
• Certain antibiotics (e.g., erythromycin, clarithromycin) – may require dose adjustment.
• Diuretics – watch for excessive blood pressure reduction.
• Recreational drugs such as poppers (amyl nitrite) – can cause dangerous drops in blood pressure.